CAMBRIDGE, Mass.--(BUSINESS WIRE)--Unum Therapeutics, a clinical-stage biopharmaceutical company focused on the development of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer, today announced that initial clinical data from the ATTCK-20-2 Phase I study and pre-clinical data on its Antibody-Coupled T cell Receptor (ACTR) platform will be presented in an oral presentation and a poster presentation, respectively, at the 59th ASH Annual Meeting, which is being held in Atlanta, GA December 9-12, 2017. The oral presentation will highlight early data from an ongoing Phase I dose escalation study, ATTCK-20-2 (ClinicalTrials.gov No. NCT02776813), of ACTR087 used in combination with rituximab in subjects with relapsed/refractory CD20+ B cell Non-Hodgkin lymphoma. In the first dose level studied (Cohort 1), ACTR087 used in combination with rituximab induced two complete responses (CR) and one partial response (PR) in patients evaluable for response (n=6), with no ACTR087-related serious adverse events (SAEs), no adverse events (AEs) leading to treatment discontinuation, no cytokine-release syndrome (CRS), and no neurotoxicity. The Company is currently enrolling and treating patients in Cohort 2. The poster presentation will provide data from non-clinical studies demonstrating the adaptability of ACTR T Cells to target T cell targets such as CD38 via combination with daratumumab, and bypass the challenges of scFv-based CAR-T cell production to effectively target CD38-expressing tumor cells.
Presentation Details:
Oral Presentation
Presentation Title: ACTR087, Autologous T Lymphocytes Expressing
Antibody Coupled T-cell Receptors (ACTR), Induces Complete Responses in
Patients with Relapsed or Refractory CD20-Positive B-cell Lymphoma, in
Combination with Rituximab
Authors (affiliation): L. Akard
(IBMT), S. Jaglowski (OSU), S. Devine (OSU), M. McKinney (Duke), M.
Vasconcelles, H. Huet, S. Ettenberg, A. Ranger, J. Abramson (MGH)
Presenter:
L. Akard (IBMT)
Presentation Date: Monday, December 11,
2017
Presentation Time: 7:45 AM
Location:
Georgia World Congress Center, Bldg A, Lvl 4, A411-A412
Session: 626.
Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell
Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials:
Immune-Based Therapeutic Approaches
Abstract Number: 580
Poster Presentation
Presentation Title: Adaptability of Antibody-Coupled T Cell
Receptor (ACTR) Engineered Autologous T Cells in Combination with
Daratumumab Over CAR-based Approaches
Authors: Taylor
Hickman, Adrianna Graziano, Katie O’Callaghan, Ryan Boomer, Eugene Choi,
Allison Nelson, Greg Motz, Jessica Sachs, Birgit Schultes, Seth
Ettenberg, and Tooba Cheema
Presenter: Taylor Hickman,
Senior Associate Scientist, Unum Therapeutics
Presentation Date:
Sunday, December 10, 2017
Presentation Time: 6:00 PM - 8:00
PM
Location: Georgia World Congress Center, Bldg A, Lvl 1,
Hall A2
Session: 703. Adoptive Immunotherapy: Poster II
Abstract
Number: 3189
The poster will be posted on Unum’s website following the presentations.
About Antibody-Coupled T cell Receptor (ACTR) Technology
Unum’s proprietary ACTR is a chimeric protein that combines components from proteins normally found on two different human immune cell types – natural killer (NK) cells and T cells – to create a novel approach to cancer cell killing. T cells bearing the ACTR receptor protein can be directed to attack a tumor by combining with a monoclonal antibody that binds antigens on the cancer cell surface.
In contrast to other T cell therapy approaches for cancer that are limited to a single cancer cell surface target and, therefore, treat a narrow set of tumors, Unum’s approach is not restricted by a specific tumor cell antigen and, thus, we believe may have applications for treating many different types of cancers when combined with the right antibodies.
Unum is developing ACTR in combination with a range of tumor-targeting antibodies for use in both hematologic and solid tumor indications. ACTR087 used in combination with rituximab, an anti-CD20 antibody, is Unum’s most advanced product candidate, currently in Phase I clinical testing for the treatment of adult patients with relapsed/refractory CD20-positive B cell non-Hodgkin lymphoma. The Company has two additional product candidates on track for imminent clinical testing under Investigational New Drug Applications (INDs) in effect with the FDA: ACTR707 used in combination with rituximab for the treatment of adult patients with relapsed/refractory CD20-positive B cell non-Hodgkin lymphoma, and ACTR087 in combination with a novel anti-BCMA antibody, SEA-BCMA, for the treatment of adult patients with relapsed/refractory multiple myeloma.
About Unum Therapeutics
Unum Therapeutics uses its proprietary Antibody-Coupled T cell Receptor (ACTR) technology in combination with tumor-targeting antibodies, to activate the body’s own immune system to fight cancer. Unum is actively building a pipeline of ACTR programs in combination with a wide range of proprietary, tumor-targeting antibodies for use in both hematologic and solid tumor indications. The Company is headquartered in Cambridge, MA. For more information, visit www.unumrx.com/.
